soda

Osiris’ stem cell drug fails in two late-stage trials

(Reuters) - Adult stem cell research firm Osiris Therapeutics Inc said two late-stage trials testing its lead product to treat a rare condition that affects bone marrow transplant patients failed to meet the main study goals.

Read More »